Threshold Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of drugs targeting the severe hypoxia in the microenvironment of solid tumors and the bone marrows of patients with hematological malignancies. The company’s lead investigational small molecule, TH-302, is evaluated in two pivotal Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; and in various earlier-stage clinical trials for therapeutic areas, including advanced leukemias, multiple myeloma, renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. It has a license and co-development agreement with Merck KGaA to co-develop and commercialize TH-302; and license agreement with Eleison Pharmaceuticals, Inc. for the development and commercialization of glufosfamide, which is used for the treatment of cancer in humans and animals. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.

Key Statistics